Bhutan HPV National Vaccination Program
Active Between: 2010-2016
Contributing to SDGs…
MSD and the Australian Cervical Cancer Foundation (ACCF) partnered with the Royal Government of Bhutan to establish the first ever national HPV vaccination program in a lower-middle-income country.
Australian Cervical Cancer Foundation (ACCF)
The Royal Government of Bhutan
In 2010, MSD and the Australian Cervical Cancer Foundation (ACCF) partnered with the Royal Government of Bhutan to establish the first ever national HPV vaccination program in a lower-middle-income country (LMIC). MSD donated GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for the first year of the six-year program and over 130,000 doses were administered, with approximately 90% of eligible 12 to 18-year-old females receiving the complete regimen. After the first year, ACCF provided financial support to the Royal Government of Bhutan to secure doses of GARDASIL at the access price offered by MSD.
Bhutan continues to demonstrate one of the highest coverage rates for HPV vaccination in the world and it is beginning to demonstrate impact. A recent publication revealed that among women younger than 27 years who were targeted by the vaccination program, the overall and indirect adjusted vaccine efficacy was 93% (CI, 87% to 97%) and 88% (CI, 69% to 95%), respectively. No impact on nonvaccine HPV types was detectable. (Baussano, Tshomo, et al).
Bhutan continues its global leadership in HPV vaccination. Following a one-year donation of HPV vaccine from MSD in 2020, the Bhutan Ministry of Health recently announced its intention to begin HPV vaccination for boys, and become one of the very first LMICs to do so.
SDGs THE PARTNERSHIP CONTRIBUTES TO
SDG 3: Good Health and Wellbeing
- 3.1: Reduce Maternal Mortality
- 3.2: Reduce Under-5 Mortality
- 3.7: Access to sexual and reproductive health-care services
SDG 17: Partnerships for the Goals